RxDoctor Payments Data

Gregory Naberhaus

Optometrist · Coral Gables, FLNPI 1982012233

Payments from drug & device makers

$4,055in general payments, 2019–2025

Across 56 payments — averaging $72.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coopervision Inc.$1K
  • AbbVie$651
  • Alcon$578
  • Sun Pharmaceutical Industries Inc.$282
  • Sight Sciences, Inc.$270
  • Glaukos Corporation$216
  • plus $953 from 9 others

What the payments were for

  • Food & beverage$4,055100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,055 in reported general payments places this provider in the 85th percentile of 3,166 optometrist providers in Florida.

See all optometrist providers in Florida

Medicare billing

Part B allowed, 2024
$51,876
Medicare patients
307
Services billed
538

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine27$23,932
LumiganBimatoprost29$14,195
CombiganBrimonidine Tartrate/Timolol20$8,232
SimbrinzaBrinzolamide/Brimonidine Tart22$7,369
Latanoprost137$2,261
Prednisolone Acetate24$975
Timolol Maleate46$631
Tobramycin-DexamethasoneTobramycin/Dexamethasone15$603
Dorzolamide Hcl22$419
Doxycycline Hyclate15$325
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat15$228

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$651$46,35976 claims
AlconSimbrinza$578$7,36922 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,166 optometrist providers in Florida.

Other optometrist in Coral Gables

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →